CelcuityCELC
CELC
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
22,800% more call options, than puts
Call options by funds: $229K | Put options by funds: $1K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
23% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 30
0.72% more ownership
Funds ownership: 81.11% [Q3] → 81.83% (+0.72%) [Q4]
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
2% less funds holding
Funds holding: 105 [Q3] → 103 (-2) [Q4]
11% less capital invested
Capital invested by funds: $450M [Q3] → $402M (-$47.8M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$29
175%
upside
Avg. target
$29
175%
upside
High target
$29
175%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum 11% 1-year accuracy 18 / 162 met price target | 175%upside $29 | Buy Maintained | 6 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 days ago
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call
MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Monday, March 31, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Neutral
GlobeNewsWire
1 month ago
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences
MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Positive
Seeking Alpha
1 month ago
Celcuity's High-Stakes Oncology Bet Is Underappreciated
Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash position with 13 quarters of runway but faces high R&D expenses and no revenue stream, making it reliant on future funding. Gedatolisib's dual inhibition of PI3K and mTOR may offer a differentiated safety profile and efficacy, potentially capturing market share in breast and prostate cancer.

Neutral
GlobeNewsWire
3 months ago
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months

Neutral
Seeking Alpha
4 months ago
Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript
Celcuity Inc. (NASDAQ:CELC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Apoorva Chaloori - ICR Westwicke, Investor Relations Brian Sullivan - Co-Founder & Chief Executive Officer Vicky Hahne - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Brad Canino - Stifel Tara Bancroft - TD Cowen Chase Knickerbocker - Craig Hallum Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in listen-only mode.

Neutral
GlobeNewsWire
4 months ago
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the third quarter ended September 30, 2024 and other recent business developments.

Neutral
GlobeNewsWire
4 months ago
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Neutral
GlobeNewsWire
4 months ago
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Negative
GuruFocus
5 months ago
Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings
On September 30, 2024, Morgan Stanley executed a significant transaction involving the sale of 1,443,913 shares of Celcuity Inc (NASDAQ: CELC), a clinical-stage biotechnology company. This move reduced their holding by 50.92%, leaving them with 1,391,552 shares.

Positive
Zacks Investment Research
6 months ago
Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at an 87.6% upside potential for Celcuity (CELC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Charts implemented using Lightweight Charts™